CDP-870. Celltech/Pfizer.

Abstract

Celltech Group plc (formerly Celltech Chiroscience), in collaboration with Pfizer Inc (formerly Pharmacia Corp), is developing CDP-870, a polyethylene glycol (PEG)ylated anti-TNF antibody fragment, for the potential treatment of certain autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Crohn's disease (CD). In October 2002, Pharmacia initiated phase III trials for RA and at this time Celltech anticipated initiating phase III trials for CD in mid-2003.

• Authors: Stefan Rose-John, Heidi Schooltink
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 5 Pg. 588-92 (May 2003) ISSN: 1472-4472 [Print] England
• PMID: 12833654 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Immunoglobulin Fab Fragments
• Polyethylene Glycols
• Certolizumab Pegol

Topics

• Animals
• Antibodies, Monoclonal, Humanized
• Autoimmune Diseases (drug therapy)
• Certolizumab Pegol
• Clinical Trials as Topic (statistics & numerical data)
• Humans
• Immunoglobulin Fab Fragments
• Polyethylene Glycols (pharmacology, therapeutic use)
• Technology, Pharmaceutical (legislation & jurisprudence, methods)